<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297852</url>
  </required_header>
  <id_info>
    <org_study_id>VEGJUICE</org_study_id>
    <nct_id>NCT04297852</nct_id>
  </id_info>
  <brief_title>The Function of Nutrition Rich Vegan Drink on Inflammatory Bowel Disease</brief_title>
  <official_title>The Function of Nutrition Rich Vegan Drink on Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Bendix Jeppesen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Future Food Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project, would be to develop a new formula, with high nutrition content on a
      vegan basis. The investigators expect to produce this novel vegan-based juice product, which
      does not exist on the marked today. The juice would consist of different selected varieties
      of vegetables and fruits. Beside the vegetables, the juice will also contain plant oils to
      increase the calorie level, as well as a protein sources containing amino acids with high
      anabolic effects.

      The products will be tested in an intervention study on patients with inflammatory bowel
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory factors</measure>
    <time_frame>3 weeks</time_frame>
    <description>F-calprotectin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Recovery</condition>
  <arm_group>
    <arm_group_label>Vegan drink</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vegan drink</intervention_name>
    <description>Vegan based drink containing vegetables, fruits and plant oils. Dose: 500 mL a day</description>
    <arm_group_label>Vegan drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Placebo drink Dose: 500 mL a day</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 85 years old

          -  Diagnosed with or show signs of UC or Crohns disease

          -  Mild symptoms i.e intestinal symptoms

          -  Has had the same medicin the previous week before starting in the study

        Exclusion Criteria:

          -  Food or vegetable allergi

          -  Cognitive diseases e.g alzheimers or dementia

          -  Has diabetes requiring insulin or GLP-1 analog treatment (NB: No does include T2D
             patients, taking tablets or other diabetes therapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per B Jeppesen, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of clinical medicin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Per B Jeppesen, Prof</last_name>
    <phone>28151877</phone>
    <email>per.bendix.jeppesen@clin.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus university</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per B Jeppesen, Prof</last_name>
      <email>per.bendix.jeppesen@clin.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Per Bendix Jeppesen</investigator_full_name>
    <investigator_title>Associate. Prof, Phd, Diabetes and hormone diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

